PMID- 12095976
OWN - NLM
STAT- MEDLINE
DCOM- 20020913
LR  - 20190922
IS  - 1068-9265 (Print)
IS  - 1068-9265 (Linking)
VI  - 9
IP  - 6
DP  - 2002 Jul
TI  - Presence of the human leukocyte antigen class II gene DRB1*1101 predicts 
      interferon gamma levels and disease recurrence in melanoma patients.
PG  - 587-93
AB  - BACKGROUND: Increased interferon gamma (IFN-gamma) levels are an independent 
      predictor of melanoma recurrence. Human leukocyte antigen (HLA) class II genes 
      can regulate cytokine production; we investigated whether these genes would 
      predict IFN-gamma levels and recurrence in melanoma patients. METHODS: Of 591 
      patients who presented with localized melanoma, 579 underwent identification of 
      HLA class II alleles; 233 melanoma patients and 90 controls underwent 
      determination of plasma IFN-gamma levels. HLA class II genes were examined for 
      association with IFN-gamma levels and disease recurrence. RESULTS: After a median 
      follow-up of 60 months, melanoma patients with IFN-gamma levels above the mean 
      control value were more likely to have developed disease recurrence compared with 
      patients with levels below the mean. The HLA class II gene HLA-DRB1*1101 was the 
      strongest predictor of recurrence, and HLA-DRB1*1101-positive melanoma patients 
      had increased levels of IFN-gamma compared with patients lacking the gene. 
      CONCLUSIONS: Among patients with localized melanoma, both HLA-DRB1*1101 and 
      increased IFN-gamma levels were associated with an increased risk for recurrence; 
      HLA-DRB1*1101-positive patients had relatively increased levels of IFN-gamma. HLA 
      class II genes may mediate cytokine production in melanoma patients, and this 
      mechanism may help determine the risk of disease recurrence.
FAU - Lee, Jeffrey E
AU  - Lee JE
AD  - Department of Surgical Oncology, The University of Texas M. D. Anderson Cancer 
      Center, Houston 77030, USA. jelee@notes.mdacc.tmc.edu
FAU - Abdalla, Joseph
AU  - Abdalla J
FAU - Porter, Geoffrey A
AU  - Porter GA
FAU - Bradford, Loretta
AU  - Bradford L
FAU - Grimm, Elizabeth A
AU  - Grimm EA
FAU - Reveille, John D
AU  - Reveille JD
FAU - Mansfield, Paul F
AU  - Mansfield PF
FAU - Gershenwald, Jeffrey E
AU  - Gershenwald JE
FAU - Ross, Merrick I
AU  - Ross MI
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Ann Surg Oncol
JT  - Annals of surgical oncology
JID - 9420840
RN  - 0 (HLA-DR Antigens)
RN  - 0 (HLA-DRB1 Chains)
RN  - 82115-62-6 (Interferon-gamma)
SB  - IM
CIN - Ann Surg Oncol. 2002 Oct;9(8):723-4. PMID: 12374654
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Alleles
MH  - Case-Control Studies
MH  - Disease-Free Survival
MH  - Female
MH  - Follow-Up Studies
MH  - HLA-DR Antigens/*genetics
MH  - HLA-DRB1 Chains
MH  - Humans
MH  - Interferon-gamma/blood/*genetics
MH  - Male
MH  - Melanoma/blood/*genetics/mortality
MH  - Middle Aged
MH  - Multivariate Analysis
MH  - Neoplasm Recurrence, Local/epidemiology/*genetics
MH  - Prognosis
MH  - Texas/epidemiology
EDAT- 2002/07/04 10:00
MHDA- 2002/09/14 10:01
CRDT- 2002/07/04 10:00
PHST- 2002/07/04 10:00 [pubmed]
PHST- 2002/09/14 10:01 [medline]
PHST- 2002/07/04 10:00 [entrez]
AID - 10.1007/BF02573896 [doi]
PST - ppublish
SO  - Ann Surg Oncol. 2002 Jul;9(6):587-93. doi: 10.1007/BF02573896.